Literature DB >> 28674051

Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients.

Ryan M Rivosecchi1, Cornelius J Clancy2,3,4, Ryan K Shields2,3, Christopher R Ensor1,5, Michael A Shullo1,5, Bonnie A Falcione1,5, Raman Venkataramanan6,7, M Hong Nguyen8,3.   

Abstract

We evaluated the interaction between isavuconazole and tacrolimus among 55 organ transplant recipients. After isavuconazole discontinuation, the tacrolimus concentration/dose ratio normalized by weight (C/D) was reduced by 16%. Liver transplant recipients experienced the largest C/D reduction. A 1.3-fold decrease in tacrolimus daily dose was required to maintain desired tacrolimus levels. There was considerable interpatient variability in the magnitude of the drug interaction. Tacrolimus doses should not be adjusted uniformly but, rather, be guided by therapeutic drug monitoring.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  drug interactions; isavuconazole; pharmacokinetics; tacrolimus; zygomycetes

Mesh：

Substances：

Year:  2017        PMID： 28674051      PMCID： PMC5571345          DOI： 10.1128/AAC.00970-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes.

Authors:  Shimin Zhang; Venkateswaran C Pillai; Sripal Reddy Mada; Steve Strom; Raman Venkataramanan
Journal:  Xenobiotica       Date:  2011-11-22       Impact factor: 1.908

2.  Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.

Authors:  A Schmitt-Hoffmann; B Roos; J Spickermann; M Heep; E Peterfaí; D J Edwards; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  2009-08-10       Impact factor: 5.191

Review 3.  Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients.

Authors:  P E Wallemacq; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.

Authors:  Francisco M Marty; Luis Ostrosky-Zeichner; Oliver A Cornely; Kathleen M Mullane; John R Perfect; George R Thompson; George J Alangaden; Janice M Brown; David N Fredricks; Werner J Heinz; Raoul Herbrecht; Nikolai Klimko; Galina Klyasova; Johan A Maertens; Sameer R Melinkeri; Ilana Oren; Peter G Pappas; Zdeněk Ráčil; Galia Rahav; Rodrigo Santos; Stefan Schwartz; J Janne Vehreschild; Jo-Anne H Young; Ploenchan Chetchotisakd; Sutep Jaruratanasirikul; Souha S Kanj; Marc Engelhardt; Achim Kaufhold; Masanori Ito; Misun Lee; Carolyn Sasse; Rochelle M Maher; Bernhardt Zeiher; Maria J G T Vehreschild
Journal:  Lancet Infect Dis       Date:  2016-03-09       Impact factor: 25.071

5.  Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.

Authors:  K E Thummel; D D Shen; T D Podoll; K L Kunze; W F Trager; C E Bacchi; C L Marsh; J P McVicar; D M Barr; J D Perkins
Journal:  J Pharmacol Exp Ther       Date:  1994-10       Impact factor: 4.030

6.  Drug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring.

Authors:  T Kim; T Jancel; P Kumar; A F Freeman
Journal:  J Clin Pharm Ther       Date:  2015-08-06       Impact factor: 2.512

7.  Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Markus Heep; Michael Schleimer; Erhard Weidekamm; Tom Brown; Michael Roehrle; Christoph Beglinger
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938

8.  Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Jürgen Maares; Markus Heep; Jochen Spickerman; Erhard Weidekamm; Tom Brown; Michael Roehrle
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938

9.  Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults.

Authors:  Andreas H Groll; Amit Desai; David Han; Corrie Howieson; Kota Kato; Shahzad Akhtar; Donna Kowalski; Christopher Lademacher; William Lewis; Helene Pearlman; Debra Mandarino; Takao Yamazaki; Robert Townsend
Journal:  Clin Pharmacol Drug Dev       Date:  2016-07-25

10.  Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment.

Authors:  Amit Desai; Anne-Hortense Schmitt-Hoffmann; Salim Mujais; Robert Townsend
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191
View more
  8 in total

1.  Reply to Baud and Houzé, "Should In Vitro and In Vivo Studies on Antimicrobial Agents during Continuous Renal Replacement Therapy Comply with General Principles of Pharmacokinetics?"

Authors:  E Wenzler; M Biagi; X Tan; D A Butler
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

2.  Invasive pulmonary aspergillosis after liver transplantation: lessons from successfully treated cases and review of the literature.

Authors:  Kodai Abe; Masahiro Shinoda; Shunsuke Uno; Hideaki Obara; Minoru Kitago; Yuta Abe; Tomoyuki Hishida; Hiroshi Yagi; Yasushi Hasegawa; Yuko Kitagawa
Journal:  Surg Today       Date:  2021-03-18       Impact factor: 2.549

3.  Effects of antifungal drugs on the plasma concentrations and dosage of tacrolimus in kidney transplant patients.

Authors:  Shuqiao Cheng; Mimi Tang; Jie Du; Tao Yin
Journal:  Eur J Hosp Pharm       Date:  2020-10-05

4.  Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.

Authors:  Xuemei Wu; Cornelius J Clancy; Ryan M Rivosecchi; Wenchen Zhao; Ryan K Shields; Rachel V Marini; Raman Venkataramanan; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 5.  Endemic Mycoses in Solid Organ Transplant Recipients.

Authors:  Jeremy S Nel; Luther A Bartelt; David van Duin; Anne M Lachiewicz
Journal:  Infect Dis Clin North Am       Date:  2018-09       Impact factor: 5.982

Review 6.  Review of Pharmacologic Considerations in the Use of Azole Antifungals in Lung Transplant Recipients.

Authors:  Megan E Klatt; Gregory A Eschenauer
Journal:  J Fungi (Basel)       Date:  2021-01-22

7.  Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study).

Authors:  Arnau Monforte; Ibai Los-Arcos; Maria Teresa Martín-Gómez; David Campany-Herrero; Judith Sacanell; Cristina Berastegui; Ester Márquez-Algaba; Abiu Sempere; Xavier Nuvials; Maria Deu; Lluís Castells; Francesc Moreso; Carles Bravo; Joan Gavaldà; Oscar Len
Journal:  Microbiol Spectr       Date:  2022-02-16

Review 8.  Recent advances in understanding and managing infectious diseases in solid organ transplant recipients.

Authors:  Claire Aguilar; Shahid Husain; Olivier Lortholary
Journal:  F1000Res       Date:  2018-05-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.